May 18, 2017

ALEXANDRIA, Va. -- The American Academy of PAs (AAPA) and CancerLinQ LLC announced today that they will be entering a partnership, with AAPA contributing expertise to the CancerLinQ® platform and potentially leveraging CancerLinQ Discovery™ for queries that will assist research efforts in the PA community aimed at improving the quality of patient care.

May 15, 2017

ALEXANDRIA, Va. --  CancerLinQ LLC, a wholly owned nonprofit subsidiary of the American Society of Clinical Oncology (ASCO®), has announced that Wendy S. Rubinstein, MD, PhD, FACMG, FACP, will be its first Division Director, Clinical Data Management and Curation. Rubinstein will oversee the team working to securely process and analyze the CancerLinQ® platform's patient data from millions of electronic health records to give personalized insights than can improve the quality of care for patients with cancer.

May 9, 2017

ALEXANDRIA, Va. --  CancerLinQ LLC, a wholly owned nonprofit subsidiary of the American Society of Clinical Oncology (ASCO), and the College of American Pathologists (CAP) announced today that they will be partnering to bolster the expertise being provided to the CancerLinQ® platform, a real-world, big data initiative focused on cancer patient medical information, aimed at improving the quality of patient care and outcomes.

May 9, 2017

The American Society of Clinical Oncology (ASCO) congratulates Scott Gottlieb, MD, on his confirmation as Commissioner of the Food and Drug Administration (FDA). With more than 1.7 million new cancer diagnoses made in the United States every year, millions of individuals with cancer and their families rely on the FDA to provide critical oversight and evaluation of the safety and efficacy of new medical products as well as those in routine clinical use.

May 8, 2017

Alexandria, VA – The American Society of Clinical Oncology (ASCO) has released findings from an ASCO-National Cancer Institute (NCI) collaboration that explored centralizing the development of coverage analyses for multi-site cancer clinical trials. In an ASCO special article published today in the Journal of Oncology Practice“Feasibility of a Centralized Clinical Trials Coverage Analysis: A Joint Initiative of the American Society of Clinical Oncology and the National Cancer Institute,” the authors assert that developing a centralized system for coverage analysis is a feasible way to address key issues and reduce administrative burdens for cancer research sites managing billing compliance, with potential for widespread benefits across the cancer research field.

May 4, 2017

ALEXANDRIA, Va. --  CancerLinQ LLC, a wholly-owned nonprofit of the American Society of Clinical Oncology (ASCO), has announced a partnership with the Oncology Nursing Society (ONS). CancerLinQ will draw on ONS's expertise and thought leadership as it continues to provide a robust quality improvement and data-sharing platform to oncology practices and cancer centers. The collaboration builds on the CancerLinQ® Ambassadors Program, which the two organizations launched earlier this year

May 2, 2017

ALEXANDRIA, Va. --  CancerLinQ LLC, a wholly owned nonprofit subsidiary of the American Society of Clinical Oncology (ASCO®), has announced that Santa Clara Valley Medical Center (SCVMC) in San Jose, Calif. has signed an agreement to participate in the CancerLinQ® platform. 

May 1, 2017

ASCO applauds Congress for its leadership in providing an additional $2 billion in funding for the National Institutes of Health (NIH). This increase reaffirms the United States' longstanding, bipartisan commitment to scientific research, and will reinvigorate the scientific community as it continues to rebuild after a decade of flat funding. It also offers hope to millions of Americans and their families who face a cancer diagnosis every year. 

May 1, 2017

ASCO has released a Strategic Plan for Increasing Racial and Ethnic Diversity in the Oncology Workforce, which aims to promote the development of an oncology workforce that is culturally competent and equipped to care for a diverse population of patients with cancer.  

April 28, 2017

ASCO strongly opposes the American Health Care Act (AHCA) as currently proposed, and urges a “No” vote on the bill in the House of Representatives because it does not meet our previously announced principles. We believe healthcare reform must ensure meaningful access to high-quality care for any American with cancer. 

April 25, 2017

ASCO applauds the California legislature for being the first state body of lawmakers in the nation to consider legislation that is designed to specifically improve clinical pathways in oncology. Clinical pathways, when appropriately designed and implemented, are evidence-based treatment management tools used to support delivery of high-quality cancer care for specific patient presentations. 

April 18, 2017

The American Society of Clinical Oncology (ASCO) opposes payer-imposed utilization management policies that restrict patient access to high-quality, high-value cancer care. In a statement released today, ASCO asserts that in modern cancer care there is frequently a lack of interchangeable clinical options, and that optimal cancer care requires patient access to the most medically appropriate drug at the most opportune time based on the highest quality evidence. 

April 6, 2017

The American Society of Clinical Oncology (ASCO) today announced that Alexander Chin, MD, MBA, and Joanna C. Yang, MD, have been selected for the 2017-2018 ASCO Health Policy Fellowship program, now entering its second year.  

April 5, 2017

ALEXANDRIA, Va. — Today, the American Society of Clinical Oncology, Inc. (ASCO®) announced that Instituto de Oncologia do Vale (IOV) has become the first practice in Brazil to receive Quality Oncology Practice Initiative (QOPI®) certification through QOPI Certification Program, LLC (QCP). IOV is the second international practice to achieve this milestone in demonstrating the quality of care it provides to oncology patients.

April 4, 2017

In a position statement released today, The American Society of Clinical Oncology (ASCO) stated its support for increased access to investigational new treatment options for patients with cancer, while raising serious concerns about recently proposed federal "right-to-try" (RTT) legislation as well as enacted state RTT laws. ASCO said these measures lack adequate patient protections and do not remove any of the major barriers patients face in accessing investigational drugs outside of clinical trials.